Iron deficiencies in pregnancy and their pharmacotherapy

Abstract

I.N. Korotkikh, O.V. Litvinenko N.N. Burdenko Voronezh State Medical University, Voronezh, Russian Federation Abstract Iron deficiency anemia (IDA) is a common complication of pregnancy which have negative health effects for both mothers and their babies. Adequate therapy for IDA is an effective treatment for anemia in pregnancy. The aim of this study was to assess the efficacy of IDA treatment in pregnant women with Tardiferon. 45 pregnant women with IDA stage 1 were followed-up in 2019. All women were prescribed with prolong-release ferrous sulfate (Tardyferon). Treatment duration was 30 days (80 mg/1 tablet daily). Blood count was evaluated after 1 month. In pregnant women who received Tardyferon, the levels of hemoglobin, erythrocytes, and hematocrit as well as serum iron, ferritin, and transferrin saturation have significantly increased. 7 women (15.6%) have reported on adverse effects (i.e., constipation and obstructed defecation). Treatment was generally well tolerated thus providing good adherence to therapy. Therefore, in pregnant women with IDA Tardyferon improves blood count a nd results in clinical improvement. Keywords: ferrous sulfate, iron deficiency anemia, pregnancy, Tardyferon. For citation: Korotkikh I.N., Litvinenko O.V. Iron deficiencies in pregnancy and their pharmacotherapy. Russian Journal of Woman and Child Health. 2019;2(4):292–295.